Paclitaxel

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific Yew tree, Taxus brevifolia and named it 'taxol'. When it was developed commercially by Bristol-Myers Squibb (BMS) the generic name was changed to 'paclitaxel' and the BMS compound is sold under the trademar... more

Medicine

ATC Code:

  • L01CD01

Drugbank:

  • APRD00259

Pubchem:

  • 36,314

CAS Number:

  • 33069-62-4

Used To Treat:

top ↑

Facts from the Community

From the BioVenturist base

Indication or disease:

Therapeutics Disease Phase of development Notes
  • Indicated for patients who have not received chemotherapy for metastatic HER2-negative breast cancer.
  • Indicated for unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer.
View entire collection »
top ↑

These people have edited this topic:

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

The original description for Paclitaxel was automatically generated from Wikipedia.org licensed under the GNU Free Documentation License.
[1]
Learn more about Freebase licensing and attribution